The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How should genomic assessment in MF be performed?

Sep 18, 2020

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub spoke to Raajit K. Rampal, Memorial Sloan Kettering Cancer Center, New York, US. We asked: How should genomic assessment in myelofibrosis be performed?

How should genomic assessment in MF be performed?

An increased understanding of the genetic drivers of MPN has been observed over the past decade, and several mutations have been associated with differential prognosis and response to treatment. Therefore, Raajit Rampal suggests that patients should undergo a full genetic assessment at the time of initial evaluation as standard of care in the MPN setting.